TENX Tenax Therapeutics Inc
Company Analysis
Latest News
Adar1 Bets $1.8 Million on Tenax After a Failed Drug Trial — Is Smart Money Seeing Something the Market Doesn't?
Shares of Tenax Therapeutics surged 17.6% to $2.17 after Adar1 Capital Management disclosed a major stock purchase just two weeks after the company's most...
🟢 Tenax Therapeutics is trading 17.57% up today after Adar1 Capital disclosed a $1.8 million share purchase
Tenax Therapeutics is trading 17.57% up at $2.17 after Adar1 Capital Management disclosed approximately $1.8 million in share purchases. - The investment firm...
Tenax Therapeutics jumps 13%, following $1.8 million Adar1 share purchase
Shares of Tenax Therapeutics rose nearly 13% in Tuesday's pre-market session. Adar1 Capital Management disclosed the purchase of over $1.8 million in company...
🟢 Tenax Therapeutics is trading 10.81% up today in pre-market with no confirmed catalyst identified
Tenax Therapeutics is trading at $2.05, +10.81% in pre-market, with no confirmed company-specific catalyst identified. - No new company-specific announcement...
🟢 Tenax Therapeutics is trading 7.05% up in pre-market
Tenax Therapeutics is trading 7.05% up now at $1.98 after no clear company-specific catalyst was identified for August 25, 2026. - The latest major...
🟢 Tenax Therapeutics is trading 12.97% up in after-hours trading
Tenax Therapeutics is trading 12.97% up at $2.09 in after-hours trading, with no clear company-specific catalyst identified for August 24, 2026. - The latest...
🟢 Tenax Therapeutics is trading 5% up today despite no clear catalyst
Tenax Therapeutics is trading 5.36% up at $1.84, with no clear catalyst identified. • No major August 24, 2026 company announcement or clearly attributed...
🔴 Tenax Therapeutics is trading 5% down today as biotech sector reverses rally
Tenax Therapeutics is trading 5.19% down now at $1.80 after the broader biotech sector reversed Wednesday’s rally. - XBI is down 2.47% during the regular...
🟢 Tenax Therapeutics is trading 10.6% up today after positive Phase 3 melanoma vaccine results
Tenax Therapeutics is trading 10.6% up at $1.88 as biotechnology sentiment improves following positive Phase 3 melanoma vaccine results from Moderna and...
🟢 Tenax Therapeutics rises 5.9% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Tenax Therapeutics is trading 5.3% down today as Nasdaq Composite falls 1.33%
Tenax Therapeutics is trading 5.3% down now at $1.62 amid broader market weakness. - The Nasdaq Composite is down 1.33%, while the S&P 500 is down 0.60%. - No...
🔴 Tenax Therapeutics is trading 5% down today
Tenax Therapeutics is trading at $1.71 (-5.00%), with no new company announcement clearly explaining the August 17, 2026 decline. - The stock remains highly...
🟢 Tenax Therapeutics is trading 5.83% up today amid rebound after Phase 3 LEVEL trial failure
Tenax Therapeutics is trading 5.83% up at $1.91, with the move appearing to be a volatile rebound following the August 10 Phase 3 LEVEL trial failure. - After...
RTW Investments Buys 10% Tenax Stake, Following 90% Stock Price Crash
RTW Investments, LP disclosed a 9.99% passive ownership stake in Tenax Therapeutics in an SEC filing on August 14, 2026. The firm reported beneficial ownership...
🟢 Tenax Therapeutics is trading 10.47% up today after LEVEL trial missed primary and secondary endpoints
Tenax Therapeutics is trading 10.47% up now at $1.90, rebounding after the August 10, 2026 collapse triggered by disappointing Phase 3 LEVEL trial results. -...
🟢 Tenax Therapeutics is trading 6.69% up today on rebound from Phase 3 LEVEL trial selloff
Tenax Therapeutics is trading 6.69% up now at $1.83, extending its rebound after the August 10, 2026 collapse caused by disappointing Phase 3 LEVEL trial...
🟢 Tenax Therapeutics is trading 5.6% up after rebound from failed Phase 3 LEVEL trial
Tenax Therapeutics is trading 5.6% up at $1.71 after rebounding from the August 10, 2026 collapse triggered by the failed Phase 3 LEVEL trial. - The study...
Tenax Therapeutics Phase 3 Trial for TNX-103 Fails to Meet Primary Endpoint
Tenax Therapeutics announced topline results from its Phase 3 LEVEL clinical trial for TNX-103 in patients with pulmonary hypertension associated with heart...
Tenax Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Tenax Therapeutics is projected to report a Q2 2026 net loss of $0.38 per share on zero revenue, with its stock currently trading at approximately $1.38...
Tenax Therapeutics Plunges 85%, Failing Phase 3 Trial for Heart Drug
Tenax Therapeutics reported that its Phase 3 LEVEL trial for TNX-103 (oral levosimendan) failed to meet its primary endpoint. The study showed no statistically...